DrugBank 3.0 is an extensively annotated database of drug and drug target information, offering comprehensive data on both small molecule and large molecule drugs. Since its last update in 2008, the database has been significantly expanded with new drugs, targets, and over 40 new data fields per drug entry, representing a 40% increase in data depth. Key additions include illustrated drug-action pathways, drug transporter data, drug metabolite data, pharmacogenomic data, adverse drug response data, ADMET data, pharmacokinetic data, computed property data, and chemical classification data. The database also features enhanced search tools for drug-drug and food-drug interactions, new resources for querying and viewing drug pathways, and detailed patent, pricing, and manufacturer data for hundreds of new drug entries. These enhancements aim to make DrugBank 3.0 a more comprehensive and accessible resource for a wide range of 'omics' applications, including pharmacogenomics, pharmacoproteomics, pharmacometabolomics, and pharmacoeconomics.DrugBank 3.0 is an extensively annotated database of drug and drug target information, offering comprehensive data on both small molecule and large molecule drugs. Since its last update in 2008, the database has been significantly expanded with new drugs, targets, and over 40 new data fields per drug entry, representing a 40% increase in data depth. Key additions include illustrated drug-action pathways, drug transporter data, drug metabolite data, pharmacogenomic data, adverse drug response data, ADMET data, pharmacokinetic data, computed property data, and chemical classification data. The database also features enhanced search tools for drug-drug and food-drug interactions, new resources for querying and viewing drug pathways, and detailed patent, pricing, and manufacturer data for hundreds of new drug entries. These enhancements aim to make DrugBank 3.0 a more comprehensive and accessible resource for a wide range of 'omics' applications, including pharmacogenomics, pharmacoproteomics, pharmacometabolomics, and pharmacoeconomics.